Frontlight ResearchEarly access
Enrolling by invitationPhase 2
A Global Phase 2 Extension Study of Brogidirsen in Boys With Duchenne Muscular Dystrophy
Key facts
- Who runs it
- NS Pharma, Inc.
- Where
- Aurora, Cincinnati, and Richmond, United StatesSee the 3 sitesAlso in 6 other countries, 14 sites
- Trial code
- Status
- Enrolling by invitation
- Phase
- Phase 2
- People taking part
- 20 people, planned
- Starts
- 16 Dec 2026
- Expected to end
- 3 Sept 2029
- Type of study
- Interventional
- Treatments tested
- Brogidirsen
- Record updated
- 17 November 2026
Who can take part
- Sex
- Men only
- Healthy volunteers
- Cannot take part
The registry criteria, word for word
Show all 9 criteriaShow less
Who can take part
- Participant has successfully completed Study NS-089/NCNP-02-201
- Participant and parent(s) or legal guardian(s) are willing and able to comply with scheduled visits, investigational product (IP) administration plan, and study procedures
- Participant must be on a stable dose of glucocorticoid (GC) steroids and is expected to remain on a stable dose of GC steroid treatment for the duration of the study
- Other inclusion criteria may apply
Who cannot take part
- Participant is currently taking other investigational drug(s)
- Participant had an adverse event (AE) in Study NS-089/NCNP-02-201 that, in the judgment of the investigator and/or sponsor, precludes safe use of brogidirsen for the participant in this study
- Participant had a treatment other than brogidirsen which was made for the purpose of dystrophin or dystrophin-related protein induction after completion of Study NS-089/NCNP-02-201
- Participant is judged by the investigator to be inappropriate for this study for other reasons
- Other exclusion criteria may apply
Where in United States
Also in 6 other countries, 14 sites
- Children's Hospital ColoradoAurora, United StatesEnrolling by invitation
- Cincinnati Children's Hospital Medical CenterCincinnati, United StatesEnrolling by invitation
- Virginia Commonwealth University Health SystemRichmond, United StatesEnrolling by invitation
About the trial
What the trial wants to find out
This Phase 2, open-label, multi-center extension study will be conducted in boys with DMD who completed the 24-week Treatment Period of Study NS-089/NCNP-02-201. Brogidirsen will be administered by IV infusion once weekly for up to 120 weeks (up to a total of 144 weeks of treatment, including weekly dosing from Part 2 of Study NS-089/NCNP-02-201) or until brogidirsen is commercially available, whichever is earlier.
The group in the trial
- BrogidirsenTreatment being tested
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Contact the study team: see the registry record → Contacts and Locations
Print a page for my doctorData and sources
- Registry record
- Listed on ClinicalTrials.gov.How to verify a trial in the registry
- Official title
- A Phase 2 Open-Label Extension Study to Assess the Safety and Efficacy of Brogidirsen in Boys With Duchenne Muscular Dystrophy (DMD)
- Record updated
- 17 November 2026